Orchid Pharma Ltd (ORCHPHARMA) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Orchid Pharma reported total income of INR 227 crores for Q3 FY25 and EBITDA of INR 37 crores.
- For the nine months of FY25, total income reached INR 710 crores, a 15% increase year-over-year, driven by execution, cost optimization, and strategic initiatives.
- Nine-month EBITDA for FY25 reached INR 115 crores, up from INR 99 crores in the previous year.
- PAT for the nine months improved by 26% to INR 78 crores from INR 62 crores.
- The company prioritized maintaining healthy margins over higher volumes at reduced prices, resulting in muted sales growth despite a 20% increase in volumes.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.